Pay in 4 interest-free payments of $6.89 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Clinical trial population adjacent: Obese individuals with higher adiposity, MASLD, T2D/high HbA1c, and/or significant liver fat and metabolic panel improvement goals
Refer patients to structured education & weight management programmes Support patients to access structured education and weight management programmes where available
The 2.5 mg dose is better called the low-dose starter, because it is the labeled start and now has short direct non-diabetic data behind it. Microdosing has been used for tolerability testing, metabolic-marker support, step-down protocols, and maintenance, not for proven long-term obesity outcomes
The SUSTAIN 6 cardiovascular outcomes trial, which followed patients for a median of 2.1 years, demonstrated a 26% reduction in the primary composite endpoint of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke compared to placebo
US$ 24.28
US$ 21.96
US$ 27.50
US$ 28.49
US$ 26.95
US$ 25.20
